In PNA mice, treatment with the lower dose of GLP1/E had also superior metabolic efficacy vs
63% of participants on the 15mg dose achieved at least 20% weight loss, compared to 1.3% on placebo
Current management for MASLD primarily relies on lifestyle modifications, with limited pharmacological options
It works by decreasing appetite, prolonging feelings of fullness, and modulating fat utilization
A medical consultation is important before starting treatment, especially for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, certain endocrine cancers, pregnancy, breastfeeding, complex diabetes medication use, or a personal or family history of medullary thyroid carcinoma or MEN2
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.